Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
NCT05789030Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of iguratimod and leflunomide in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Relapse Rate of IgG4-RD at 12 months. Started Jul 2022; status: recruiting.
02
Drugs
iguratimodleflunomide
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT05789030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789030.